Moléculas en desarrollo
Obtenga más información sobre nuestros proyectos en desarrollo de I+D y ensayos en curso a continuación
Programas de desarrollo – Tumor sólido
Fármaco
Indicación
Fase 1
Fase 2
Fase 3
Tislelizumab
(anti-PD-1)Ociperlimab
(anti-TIGIT)BG-685011
(inhibidor de CDK2)BGB-43395
(inhibidor de CDK4)BG-C90742
(B7H4-ADC)BGB-C354
(B7H3-ADC)LBL-0073
(anti-LAG3)Umbrella
(combinaciones de inmunooncología [IO])Zanidatamab4
(anticuerpo específico anti-HER2)BGB-A445
(anti-OX40)BGB-15025
(inhibidor de HPK1)BGB-26808
(inhibidor de HPK1)BGB-24714
(imitador de SMAC)BGB-30813
(inhibidor de DGKζ)BGB-A3055
(anti-CCR8)Pamiparib
(inhibidor de PARP 1/2)Tarlatamab5
(DLL3 x CD3)Xaluritamig5
(STEAP1 x CD3)BGB-R046
(IL-15 prodrug)BGB-B3227
(anticuerpo específico MUC1 x CD16A)BGB-B2033
(GPC3 x 4-1BB)BG-C477
(CEA ADC)BGB-53038
(PanKRAS inhibitor)BG-C137
(FGFR2b-ADC)BGB-58067
(inhibidor de PRMT5)BG-60366
(CDAC EGFR-dirigido)No se ha establecido la seguridad y eficacia para productos o usos en investigación.
Programas de desarrollo – Hematología
Fármaco
Indicación
Fase 1
Fase 2
Fase 3
Zanubrutinib
(inhibidor de BTK)Sonrotoclax
(inhibidor de BCL2)BGB-16673
(CDAC BTK-dirigido)BGB-21447
(inhibidor de BCL2)Tislelizumab
(anti-PD-1)Ociperlimab
(anti-TIGIT)Zanubrutinib
(inhibidor de BTK)BGB-45035
(IRAK4-targeted CDAC)Blinatumomab5
(CD3 X CD19)No se ha establecido la seguridad y eficacia para productos o usos en investigación.
aPuede incluir anti-PD-1, anti-LAG3, anti-OX40 e inhibidor de HPK1.
bin combination with Zanubrutinib.
1Colaboración con Ensem; BeiGene tiene derechos globales.
2Colaboración con DualityBio; BeiGene tiene derechos globales.
3Colaboración con Leads Biolabs; BeiGene tiene derechos comerciales fuera de China.
4Colaboración con Zymeworks/Jazz; BeiGene tiene derechos comerciales en APAC/ex-Japón, Australia y Nueva Zelanda.
5Colaboración con Amgen; BeiGene tiene derechos comerciales en China.
1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; BC, breast cancer; BCL2, B-cell lymphoma 2; BsAb, bispecific antibody; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD16A, Fc receptor FcγRIIIa; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FL, follicular lymphoma; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; IRAK4, interleukin-1 receptor-associated kinase 4; KRAS, Kirsten rat sarcoma virus; LA, locally advanced; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MUC1, mucin 1; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, six-transmembrane epithelial antigen of the prostate 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.
Portfolio clínico interactivo
Videos
Mecanismo de acción de Anti-OX40
Mecanismo de acción de Anti-PD-1
Mecanismo de acción del inhibidor de CDK4
Mecanismo de acción de BTKI
Mecanismo de acción de anti-TIGIT
Mecanismo de acción de PARPI